Daniel Y. Wang, MD

Articles by Daniel Y. Wang, MD

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease

ByDouglas B. Johnson, MD, MSCI,Kathryn E. Beckermann, MD, PhD,Daniel Y. Wang, MD

April 15th 2018

In this article, we detail the experience with immune checkpoint inhibitors in patients with autoimmune disease.

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics

ByDaniel Y. Wang, MD,Jeffrey A. Sosman, MD,Douglas B. Johnson, MD, MSCI

December 15th 2015

In view of the potential for durable responses with immunotherapy, it will be important to identify the most effective and least toxic regimens for individual patients.

Latest Updated Articles

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics
December 15th 2015
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease
April 15th 2018

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)